+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cardiac Glycosides Market - Global Forecast 2026-2032- Product Image
Cardiac Glycosides Market - Global Forecast 2026-2032- Product Image
Sale

Cardiac Glycosides Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6151171
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cardiac Glycosides Market is projected to reach USD 625.72 Million in 2026. It is expected to continue growing at a CAGR of 4.74%, reaching USD 823.86 Million by 2032.

Cardiac Glycosides: Executive Overview of a Therapeutic Drug Class

Cardiac glycosides are medicines that influence cardiac contractility and conduction, with digoxin remaining the principal contemporary example. Their clinical use is concentrated in selected heart-failure and atrial-fibrillation contexts, where treatment decisions depend on patient characteristics, concomitant medicines, renal function, serum concentration monitoring, and local clinical guidance. The category is therefore defined less by broad therapeutic expansion than by targeted use within carefully managed cardiovascular care pathways.

Clinical Stewardship Is Reshaping Cardiac Glycoside Use

The landscape is shifting toward more selective prescribing, stronger medication-reconciliation practices, and closer monitoring of toxicity risk. Narrow therapeutic margins make renal impairment, electrolyte abnormalities, age-related pharmacokinetic changes, and drug interactions central to treatment decisions. Evidence-based guideline updates, the availability of alternative cardiovascular therapies, and growing emphasis on individualized care are encouraging clinicians to reassess when cardiac glycosides provide meaningful benefit relative to monitoring burden and safety considerations.

Artificial Intelligence Supports Safer, More Individualized Management

Artificial intelligence is contributing primarily as a clinical-support capability rather than as a replacement for cardiovascular expertise. Models can help identify patients at elevated risk of adverse drug events by integrating medication lists, kidney function, laboratory results, electrocardiographic data, and longitudinal records. Potential applications include dose-review prompts, interaction detection, toxicity surveillance, and prioritization of patients needing follow-up. Safe deployment requires validated datasets, transparent decision logic, clinician oversight, privacy safeguards, and monitoring for biased or poorly generalizable outputs.

Regional Differences Reflect Access, Monitoring Capacity, and Practice Norms

North America generally combines extensive cardiology infrastructure with strong access to laboratory testing and electronic prescribing, supporting structured monitoring. Europe emphasizes guideline-led use and coordinated pharmacovigilance across diverse health systems. Asia-Pacific contains highly varied access conditions, from advanced hospital networks to settings where continuity of monitoring is more difficult. Latin America faces differences in medicine availability, affordability, and specialist access. The Middle East shows substantial variation between well-resourced urban systems and more capacity-constrained settings, while Africa often confronts diagnostic, laboratory, supply-chain, and continuity-of-care limitations that affect safe long-term use.

Economic and Security Alliances Shape Coordinated Cardiovascular Care

Within ASEAN, uneven health-system capacity makes standardized monitoring and professional education particularly valuable. BRICS members span major differences in regulatory systems, domestic manufacturing, and access to specialist care. The European Union benefits from shared regulatory and pharmacovigilance structures while retaining national differences in reimbursement and clinical implementation. G7 countries typically have mature prescribing systems and stronger data infrastructure. GCC states can leverage concentrated hospital networks and investment in digital health, whereas NATO members represent a broad set of health systems where resilience, procurement continuity, and cross-border clinical preparedness remain important.

Country Context Determines Prescribing and Monitoring Priorities

Australia, Canada, France, Germany, Italy, Spain, the United Kingdom, and the United States generally have established cardiovascular services, electronic records, and monitoring capabilities, though reimbursement and guideline implementation differ. Japan and South Korea combine advanced clinical infrastructure with aging populations and a strong need for medication-safety management. China and India encompass major tertiary-care capacity alongside substantial regional variation in access and continuity. Brazil and Mexico face contrasts between private and public delivery systems. Russia’s care environment is shaped by regulatory, procurement, and health-system constraints. Across all countries, renal assessment, interaction review, patient education, and reliable access to testing are central to responsible use.

Prioritize Patient Selection, Monitoring, and Supply Resilience

Industry leaders should support evidence-based protocols that clearly define appropriate patient selection, dosing review, and treatment reassessment. Investment should focus on clinician and patient education, practical tools for renal-function and interaction checks, and interoperable systems that connect prescribing with laboratory and follow-up data. Organizations should also strengthen pharmacovigilance, prepare for shortages through diversified procurement and quality-assured supply arrangements, and evaluate digital decision-support tools in real clinical settings. Partnerships with hospitals, regulators, pharmacists, and professional societies can improve implementation without encouraging inappropriate utilization.

Methodology: Evidence-Based Synthesis of Clinical and Health-System Factors

This executive summary uses a structured qualitative assessment of cardiac glycosides as a therapeutic class. The analysis considers established pharmacology, clinical-use principles, safety and monitoring requirements, health-system capabilities, regulatory and pharmacovigilance considerations, digital-health developments, and differences across the specified regions, groups, and countries. Interpretations are framed as contextual insights rather than quantitative market claims. Artificial-intelligence implications are assessed according to plausible clinical applications, governance requirements, and the need for validation and human oversight.

The Category’s Future Depends on Precision, Safety, and System Readiness

Cardiac glycosides remain a specialized component of cardiovascular pharmacotherapy whose value depends on disciplined patient selection and monitoring. The most consequential developments are likely to involve safer medication management, better integration of clinical and laboratory information, and stronger alignment between prescribing practices and local health-system capabilities. Leaders that prioritize evidence, pharmacovigilance, responsible digital innovation, and resilient access will be best positioned to support appropriate use across diverse care environments.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cardiac Glycosides Market, by Product Type
7.1. Introduction
7.2. Digitoxin
7.3. Digoxin
7.4. Ouabain
8. Cardiac Glycosides Market, by Form
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Cardiac Glycosides Market, by Application
9.1. Introduction
9.2. Atrial Fibrillation
9.3. Atrial Flutter
9.4. Congestive Heart Failure
10. Cardiac Glycosides Market, by End Use
10.1. Introduction
10.2. Ambulatory Services
10.3. Clinics
10.4. Home Care Centers
10.5. Hospitals
11. Cardiac Glycosides Market, by Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
11.4.1. Chain Pharmacies
11.4.2. Independent Pharmacies
11.5. Wholesale Distributors
11.5.1. General Distributors
11.5.2. Specialty Distributors
12. Cardiac Glycosides Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Cardiac Glycosides Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Cardiac Glycosides Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Alchem International
16.2. Amgen Inc
16.3. Amneal Pharmaceuticals LLC
16.4. AstraZeneca plc
16.5. Aurobindo Pharma Limited
16.6. Bayer AG
16.7. Boehringer Ingelheim GmbH
16.8. C2 PHARMA
16.9. Cipla Limited
16.10. Dr. Reddy's Laboratories Ltd
16.11. Fresenius Kabi
16.12. GlaxoSmithKline plc
16.13. Hikma Pharmaceuticals PLC
16.14. Merck & Co Inc
16.15. Midas Pharma GmbH
16.16. Mylan N.V.
16.17. Novartis AG
16.18. Pfizer Inc
16.19. Sanofi S.A.
16.20. SimSon Pharma Limited
16.21. Sun Pharmaceutical Industries Ltd
16.22. Teva Pharmaceutical Industries Ltd
16.23. Vital Laboratories Pvt Ltd
16.24. Zydus Cadila
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Cardiac Glycosides Market, Years Considered for the Study
FIGURE 2. Global Cardiac Glycosides Market, Research Design
FIGURE 3. Global Cardiac Glycosides Market, Research Framework
FIGURE 4. Global Cardiac Glycosides Market, Data Triangulation
FIGURE 5. Global Cardiac Glycosides Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Cardiac Glycosides Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Cardiac Glycosides Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Cardiac Glycosides Market Size, by Form, 2025 vs 2032 (%)
FIGURE 9. Global Cardiac Glycosides Market Size, by Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Cardiac Glycosides Market Size, by Application, 2025 vs 2032 (%)
FIGURE 11. Global Cardiac Glycosides Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Cardiac Glycosides Market Size, by End Use, 2025 vs 2032 (%)
FIGURE 13. Global Cardiac Glycosides Market Size, by End Use, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Cardiac Glycosides Market Size, by Channel, 2025 vs 2032 (%)
FIGURE 15. Global Cardiac Glycosides Market Size, by Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Cardiac Glycosides Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Cardiac Glycosides Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Cardiac Glycosides Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Cardiac Glycosides Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Cardiac Glycosides Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Cardiac Glycosides Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Cardiac Glycosides Market Segmentation & Coverage
TABLE 2. Global Cardiac Glycosides Market Size, 2017-2032 (USD Million)
TABLE 3. Global Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Digitoxin Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Digitoxin Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Digitoxin Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Digoxin Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Digoxin Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Digoxin Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Ouabain Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Ouabain Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Ouabain Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 14. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Parenteral Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Parenteral Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Parenteral Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 21. Global Atrial Fibrillation Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Atrial Fibrillation Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Atrial Fibrillation Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Atrial Flutter Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Atrial Flutter Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Atrial Flutter Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Congestive Heart Failure Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Congestive Heart Failure Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Congestive Heart Failure Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 31. Global Ambulatory Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Ambulatory Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Ambulatory Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Home Care Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Home Care Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Home Care Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 44. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Chain Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Chain Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Chain Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Independent Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Independent Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Independent Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Wholesale Distributors Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Wholesale Distributors Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Wholesale Distributors Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global General Distributors Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global General Distributors Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global General Distributors Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Specialty Distributors Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Specialty Distributors Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Specialty Distributors Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Cardiac Glycosides Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Cardiac Glycosides Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 77. North America Cardiac Glycosides Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. North America Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 79. North America Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 80. North America Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 81. North America Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 82. North America Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 83. North America Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 84. North America Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 85. Latin America Cardiac Glycosides Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Latin America Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 87. Latin America Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 88. Latin America Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 89. Latin America Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 90. Latin America Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 91. Latin America Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 92. Latin America Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 93. Europe Cardiac Glycosides Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Europe Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 95. Europe Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 96. Europe Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 97. Europe Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 98. Europe Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 99. Europe Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 100. Europe Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 101. Middle East Cardiac Glycosides Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Middle East Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 103. Middle East Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 104. Middle East Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 105. Middle East Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 106. Middle East Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 107. Middle East Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 108. Middle East Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 109. Africa Cardiac Glycosides Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Africa Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 111. Africa Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 112. Africa Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 113. Africa Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 114. Africa Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 115. Africa Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 116. Africa Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 117. Global Cardiac Glycosides Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. ASEAN Cardiac Glycosides Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. ASEAN Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 120. ASEAN Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 121. ASEAN Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 122. ASEAN Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 123. ASEAN Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 124. ASEAN Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 125. ASEAN Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 126. GCC Cardiac Glycosides Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. GCC Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 128. GCC Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 129. GCC Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 130. GCC Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 131. GCC Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 132. GCC Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 133. GCC Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 134. European Union Cardiac Glycosides Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. European Union Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 136. European Union Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 137. European Union Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 138. European Union Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 139. European Union Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 140. European Union Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 141. European Union Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 142. BRICS Cardiac Glycosides Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. BRICS Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 144. BRICS Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 145. BRICS Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 146. BRICS Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 147. BRICS Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 148. BRICS Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 149. BRICS Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 150. G7 Cardiac Glycosides Market Size, by Group, 2017-2032 (USD Million)
TABLE 151. G7 Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 152. G7 Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 153. G7 Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 154. G7 Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 155. G7 Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 156. G7 Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 157. G7 Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 158. NATO Cardiac Glycosides Market Size, by Group, 2017-2032 (USD Million)
TABLE 159. NATO Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 160. NATO Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 161. NATO Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 162. NATO Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 163. NATO Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 164. NATO Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 165. NATO Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 166. Global Cardiac Glycosides Market Size, by Country, 2017-2032 (USD Million)
TABLE 167. United States Cardiac Glycosides Market Size, 2017-2032 (USD Million)
TABLE 168. United States Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 169. United States Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 170. United States Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 171. United States Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 172. United States Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 173. United States Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 174. United States Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 175. Canada Cardiac Glycosides Market Size, 2017-2032 (USD Million)
TABLE 176. Canada Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 177. Canada Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 178. Canada Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 179. Canada Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 180. Canada Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 181. Canada Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 182. Canada Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 183. Mexico Cardiac Glycosides Market Size, 2017-2032 (USD Million)
TABLE 184. Mexico Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 185. Mexico Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 186. Mexico Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 187. Mexico Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 188. Mexico Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 189. Mexico Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 190. Mexico Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 191. Brazil Cardiac Glycosides Market Size, 2017-2032 (USD Million)
TABLE 192. Brazil Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 193. Brazil Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 194. Brazil Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 195. Brazil Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 196. Brazil Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 197. Brazil Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 198. Brazil Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 199. United Kingdom Cardiac Glycosides Market Size, 2017-2032 (USD Million)
TABLE 200. United Kingdom Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 201. United Kingdom Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 202. United Kingdom Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 203. United Kingdom Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 204. United Kingdom Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 205. United Kingdom Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 206. United Kingdom Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 207. Germany Cardiac Glycosides Market Size, 2017-2032 (USD Million)
TABLE 208. Germany Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 209. Germany Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 210. Germany Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 211. Germany Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 212. Germany Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 213. Germany Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 214. Germany Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 215. France Cardiac Glycosides Market Size, 2017-2032 (USD Million)
TABLE 216. France Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 217. France Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 218. France Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 219. France Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 220. France Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 221. France Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 222. France Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 223. Russia Cardiac Glycosides Market Size, 2017-2032 (USD Million)
TABLE 224. Russia Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 225. Russia Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 226. Russia Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 227. Russia Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 228. Russia Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 229. Russia Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 230. Russia Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 231. Italy Cardiac Glycosides Market Size, 2017-2032 (USD Million)
TABLE 232. Italy Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 233. Italy Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 234. Italy Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 235. Italy Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 236. Italy Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 237. Italy Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 238. Italy Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 239. Spain Cardiac Glycosides Market Size, 2017-2032 (USD Million)
TABLE 240. Spain Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 241. Spain Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 242. Spain Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 243. Spain Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 244. Spain Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 245. Spain Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 246. Spain Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 247. China Cardiac Glycosides Market Size, 2017-2032 (USD Million)
TABLE 248. China Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 249. China Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 250. China Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 251. China Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 252. China Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 253. China Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 254. China Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 255. India Cardiac Glycosides Market Size, 2017-2032 (USD Million)
TABLE 256. India Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 257. India Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 258. India Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 259. India Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 260. India Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 261. India Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 262. India Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 263. Japan Cardiac Glycosides Market Size, 2017-2032 (USD Million)
TABLE 264. Japan Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 265. Japan Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 266. Japan Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 267. Japan Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 268. Japan Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 269. Japan Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 270. Japan Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 271. Australia Cardiac Glycosides Market Size, 2017-2032 (USD Million)
TABLE 272. Australia Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 273. Australia Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 274. Australia Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 275. Australia Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 276. Australia Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 277. Australia Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 278. Australia Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 279. South Korea Cardiac Glycosides Market Size, 2017-2032 (USD Million)
TABLE 280. South Korea Cardiac Glycosides Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 281. South Korea Cardiac Glycosides Market Size, by Form, 2017-2032 (USD Million)
TABLE 282. South Korea Cardiac Glycosides Market Size, by Application, 2017-2032 (USD Million)
TABLE 283. South Korea Cardiac Glycosides Market Size, by End Use, 2017-2032 (USD Million)
TABLE 284. South Korea Cardiac Glycosides Market Size, by Channel, 2017-2032 (USD Million)
TABLE 285. South Korea Cardiac Glycosides Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 286. South Korea Cardiac Glycosides Market Size, by Wholesale Distributors, 2017-2032 (USD Million)
TABLE 287. Global Cardiac Glycosides Market Share, by Key Player, 2025
TABLE 288. Global Cardiac Glycosides Market, Key Experts

Companies Mentioned

  • Alchem International
  • Amgen Inc
  • Amneal Pharmaceuticals LLC
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • C2 PHARMA
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd
  • Fresenius Kabi
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Merck & Co Inc
  • Midas Pharma GmbH
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc
  • Sanofi S.A.
  • SimSon Pharma Limited
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Vital Laboratories Pvt Ltd
  • Zydus Cadila

Related Topics

Related Reports

Deslanoside Powder Market - Global Forecast 2026-2032 - Product Image

Deslanoside Powder Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report - Product Image

Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report

  • Report
  • 299 Pages
  • Global
From
Cardiotonic Agents Market Report 2026 - Product Image

Cardiotonic Agents Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Dilated Cardiomyopathy Therapeutics - Global Strategic Business Report - Product Image

Dilated Cardiomyopathy Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Advancements in Cardiovascular Research and Therapeutics: Molecular and Nutraceutical Perspectives - Product Image

Advancements in Cardiovascular Research and Therapeutics: Molecular and Nutraceutical Perspectives

  • Book

About the Market

Cardiac glycosides are a class of drugs used to treat heart failure and abnormal heart rhythms. They work by increasing the force of contraction of the heart muscle, which helps the heart pump more efficiently. Cardiac glycosides are also used to treat certain types of arrhythmias, or irregular heartbeats. These drugs are typically prescribed in combination with other medications, such as diuretics and ACE inhibitors. Cardiac glycosides are an important part of the cardiovascular drug market. They are used to treat a variety of conditions, including heart failure, arrhythmias, and hypertension. They are also used to reduce the risk of stroke and other cardiovascular events. Cardiac glycosides are generally well-tolerated and have few side effects. Some of the companies in the cardiac glycoside market include Sanofi, Pfizer, Merck, and Novartis. These companies produce a variety of cardiac glycoside medications, including digoxin, lanatoside C, and ouabain. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.